5 reasons to be a Sanofi shareholder

Sanofi: a global healthcare leader

A leading player in Specialty Care, Vaccines, Consumer Healthcare and Emerging Markets.

€34,463m

2018
Company sales

€6,819m

2018
Business net income

€5.47

2018
Business EPS

Every day, more than 100,000 employees in more than 100 countries are committed to preventing diseases with vaccines, to offering innovative treatments and to supporting both those with rare diseases and the millions of people with chronic diseases.

Innovative Research and Development

A robust pipeline meeting unsatisfied medical needs which may support long-term growth.

Scientists

As of February 7, 2019

Solid financial performance

Value-creating acquisitions while maintaining financial discipline.

« We have set our FY guidance for 2019 business EPS to grow between 3% and 5% at CER. This expresses our confidence in the return to growth which began in the second half of 2018. »

Jean-Baptiste de Chatillon, EVP, Financial Director
2018 Full-Year Results Presentation

Consistent dividend increase for 25 years and high dividend yield

Strong commitment to regular shareholder returns

A responsible company

Focused on patients’ needs and committed to improving access to healthcare for all people across the globe.

responsibility

Discover Sanofi

Being a shareholder
Being a shareholder
Shareholder Handbook 2018
Shareholder Handbook 2019

Disclaimer: the information presented in this section is not an offer or a sollicitation of an offer to buy, to sell or to subscribe for any Sanofi securities. This information shall not constitue a sollicitation to invest.

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies
OK